BrainStorm Appoints Former FDA Official Peter J. Pitts as Executive Chairman
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) has appointed former FDA Associate Commissioner Peter J. Pitts as its new Executive Chairman and Chief Strategic Regulatory and Policy Officer, marking a significant leadership change for the company. Pitts will lead BrainStorm's strategic operations, including corporate partnerships, investor relations, and clinical-regulatory pathways, with a primary focus on advancing NurOwn® into Phase 3b trials under an FDA Special Protocol Assessment (SPA). This is the first SPA ever granted to an ALS therapeutic candidate. Professor Jacob Frenkel transitions from Board Chairman to Senior Advisor as part of this leadership shift. The move aims to strengthen BrainStorm's regulatory and financial strategy, particularly during high-stakes discussions with potential corporate partners and institutional investors. The company emphasizes that NurOwn® is a de-risked clinical asset with clear regulatory pathways.
Topics: clinical trials leadership change regulatory strategy